

Dr. Takashi Kohno, Director of the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) at the National Cancer Center in Japan, completed his academic journey at Kyoto University in 1989, earning a PhD from Tokyo University in 1995. He played a pivotal role in a significant clinical trial involving an RET fusion gene-targeting inhibitor, which he discovered in 2012. In 2021, he successfully obtained insurance coverage for the RET inhibitor serpercatinib. Dr. Kohno's pursuits also include developing the NCC Oncopanel, a cancer gene panel test that achieved insurance coverage in June 2019. Dr. Kohno actively drives the advancement of cancer genome medicine, utilizing gene panel test results for medical treatment and research and development.